Acute Myeloid Leukemia Clinical Trial
Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
Summary
This is an open label, multicenter Phase 1 study to determine the MTD, dosing schedule and RP2D of IMGN779 when administered as mono-therapy to adult AML patients with CD33 -positive disease.
Full Description
In the Dose Escalation Phase, patients will be assigned to one of three schedules. The MTD for all schedules will be determined from the assessment of Dose Limiting Toxicities (DLTs). The Dose Expansion Phase will consist of one cohort based on patients response to prior therapy according to the MTD selected.
Eligibility Criteria
Inclusion Criteria:
Dose Escalation: Patients with relapsed or refractory AML
Dose Expansion: Patients with relapsed AML or patients who refuse, or are not suitable candidates for induction therapy
Exclusion Criteria:
Dose Escalation: Acute Promyelocytic Leukemia
Any concurrent anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, biologic or any investigational agents (with the exception of hydroxyurea or leukapheresis for control of hyperleukocytosis) within 14 days or five half-lives of drugs, whichever is shorter, prior to Cycle 1 Day 1
AML patients with known, active leptomeningeal/central nervous system (CNS) involvement
Prior treatment with IMGN779
Women who are pregnant or breast feeding
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 7 Locations for this study
Birmingham Alabama, 35294, United States
Boston Massachusetts, 02215, United States
Albuquerque New Mexico, 87106, United States
Buffalo New York, 14263, United States
Portland Oregon, 97239, United States
Dallas Texas, 75246, United States
Houston Texas, 77030, United States
How clear is this clinincal trial information?